Tesamorelin CAS No. 218949-48-5

Primary Clinical Use

• Treatment of Excess Abdominal Fat (Lipodystrophy) in HIV-Patients: Approved to reduce excess visceral abdominal fat in HIV-infected patients with lipodystrophy.

• Mechanism of Action:

  • Binds to GHRH receptors in the pituitary gland.

  • Stimulates pulsatile release of endogenous Growth Hormone (GH).

  • GH acts on fat cells, promoting lipolysis and reducing visceral fat tissue.

Mechanism of Action

• Binds to GHRH receptors in the anterior pituitary gland.

• Stimulates the natural release of growth hormone (GH), which elevates IGF-1 (insulin-like growth factor 1) levels.

• Enhances lipolysis and reduces visceral fat, particularly in the abdomen.

Clinical Use

• Indication: Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

• Administration: Subcutaneous injection, 2 mg once daily.

• Brand Name: Egrifta®.

Side Effects / Considerations

• Common Side Effects: Injection-site reactions, arthralgia, edema, myalgia.

• IGF-1 Increase: May raise theoretical risk of neoplasia in susceptible individuals.

• Contraindications: Active malignancy.

Structural and Functional Interpretation of the Formula

• Carbon (C₂₂₁) & Hydrogen (H₃₆₆): Indicate a large, complex organic molecule with a backbone and side chains of amino acids.

• Nitrogen (N₇₂): High nitrogen count is characteristic of peptides, indicating the presence of amino groups and peptide bonds.

• Oxygen (O₆₇): Found in carboxyl groups, peptide bonds, and side chains of specific amino acids.

• Sulfur (S): Indicates the presence of at least one amino acid with a sulfur-containing side chain, such as Methionine.

What is Tesamorelin?

• Synthetic Peptide: Tesamorelin is a synthetic peptide designed in a laboratory, modified from the first 44 amino acids of the human Growth Hormone-Releasing Hormone (GHRH).

• Natural GHRH (1-44): Produced by the hypothalamus, stimulates the pituitary gland to produce and release Growth Hormone (GH).

• Tesamorelin (Modification): Replaces the first amino acid (L-Alanine) with L-Tyrosine and adds a trans-3-hexenoic acid group to the N-terminus to enhance stability and potency.

Key Characteristics Summary

• Chemical Nature: Synthetic 44-amino acid peptide analog of GHRH.

• Mechanism: GHRH receptor agonist.

• Primary Effect: Stimulates endogenous pulsatile release of Growth Hormone.

• Clinical Use: Reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.

• Trade Name: Egrifta SV® (subcutaneous injection).

Detailed Information

• Molecular Weight: Approximately 5135.86 g/mol.

• Structure: Consists of the entire 44-amino-acid sequence of human GHRH with a trans-3-hexenoic acid group added to the N-terminal tyrosine residue.

• Administration: Daily subcutaneous injection.

• Brand Name: Egrifta® (by Theratechnologies / EMD Serono).

Safety Information

• Regulation:

  • Pharmaceutical-Grade: FDA-approved and manufactured under cGMP.

  • Research-Grade: Unregulated for human use; intended for laboratory study.

• Quality Control:

  • Pharmaceutical-Grade: Extensive testing for purity, potency, and contaminants, including microbial and other impurities.

  • Research-Grade: Varies by supplier; may include HPLC purity verification, but lacks rigorous checks for contaminants.

• Intended Use:

  • Pharmaceutical-Grade: Therapeutic use in humans under medical supervision.

  • Research-Grade: Non-clinical laboratory applications only.

• Storage:

  • Pharmaceutical-Grade: Specific storage instructions for the lyophilized powder and diluent are provided to maintain stability.

  • Research-Grade: Proper storage is still required, but stability testing is less rigorous.

Product Documents

• Safety Data Sheet (SDS)
• Certificate of Analysis
• Product Brochure
• Technical Data Sheet